Homeopathy 2013; 102(01): 59-65
DOI: 10.1016/j.homp.2012.10.004
Clinical Paper
Copyright © The Faculty of Homeopathy 2012

Homeopathic treatment of premenstrual syndrome: a case series

Karine Danno
Aurélie Colas
Laurence Terzan
Marie-France Bordet

Subject Editor:
Further Information

Publication History

Received06 January 2012
revised31 October 2012

accepted31 October 2012

Publication Date:
02 January 2018 (online)

Objective: Observational, prospective study to describe the homeopathic management of premenstrual syndrome (PMS) by a group of French physicians.

Method: Women with PMS for >3 months were prescribed individualized homeopathic treatment. The intensity of 10 clinical symptoms of PMS was scored individually at inclusion and at a 3–6 month follow-up visit: absent = 0, mild = 1, moderate = 2, severe = 3. Total symptom score (range: 0–30) was calculated and compared for each patient at inclusion and at follow-up. PMS impact on daily activities (quality of life, QoL) was compared at inclusion and follow-up as: none, mild, moderate, severe, very severe.

Results: Twenty-three women were prescribed homeopathic treatment only (mean age: 39.7 years). Folliculinum (87%) was the most frequently prescribed homeopathic medicine followed by Lachesis mutus (52.2%). The most common PMS symptoms (moderate or severe) at inclusion were: irritability, aggression and tension (87%), mastodynia (78.2%) and weight gain and abdominal bloating (73.9%); and the most common symptoms at follow-up were: irritability, aggression and tension (39.1%), weight gain and abdominal bloating (26.1%) and mastodynia (17.4%). Mean global score for symptom intensity was 13.7 at inclusion and 6.3 at follow-up. The mean decrease in score (7.4) was statistically significant (p < 0.0001). Twenty-one women reported that their QoL also improved significantly (91.3%; p < 0.0001).

Conclusions: Homeopathic treatment was well tolerated and seemed to have a positive impact on PMS symptoms. Folliculinum was the most frequent homeopathic medicine prescribed. There appears to be scope for a properly designed, randomized, placebo-controlled trial to investigate the efficacy of individual homeopathic medicines in PMS.

  • References

  • 1 Brown J., O'Brien P.M., Marjoribanks J., Wyatt K. Selective serotonin reuptake inhibitors for premenstrual syndrome. Cochrane Database Syst Rev 2009; 2: CD001396.
  • 2 Steiner M., Macdougall M., Brown E. The premenstrual symptoms screening tool (PSST) for clinicians. Arch Womens Ment Health 2003; 6: 203-209.
  • 3 Halbreich U., Backstrom T., Eriksson E. et al. Clinical diagnostic criteria for premenstrual syndrome and guidelines for their quantification for research studies. Gynecol Endocrinol 2007; 23: 123-130.
  • 4 O'Brien P.M., Bäckström T., Brown C. et al. Towards a consensus on diagnostic criteria, measurement and trial design of the premenstrual disorders: the ISPMD Montreal consensus. Arch Womens Ment Health 2011; 14: 13-21.
  • 5 Freeman E.W., Halberstadt S.M., Rickels K., Legler J.M., Lin H., Sammel M.D. Core symptoms that discriminate premenstrual syndrome. J Womens Health (Larchmt) 2011; 20: 29-35.
  • 6 Steiner M., Peer M., Palova E., Freeman E.W., Macdougall M., Soares C.N. The Premenstrual Symptoms Screening Tool revised for adolescents (PSST-A): prevalence of severe PMS and premenstrual dysphoric disorder in adolescents. Arch Womens Ment Health 2011; 14: 77-81.
  • 7 Halbreich U. The diagnosis of premenstrual syndromes and premenstrual dysphoric disorder – clinical procedures and research perspectives. Gynecol Endocrinol 2004; 19: 320-334.
  • 8 Dennerstein L., Lehert P., Bäckström T.C., Heinemann K. The effect of premenstrual symptoms on activities of daily life. Fertil Steril 2010; 94: 1059-1064.
  • 9 Freeman E.W. Therapeutic management of premenstrual syndrome. Expert Opin Pharmacother 2010; 11: 2879-2889.
  • 10 Moline M.L., Zendell S.M. Evaluating and managing premenstrual syndrome. Medscape Womens Health 2000; 5: 1.
  • 11 Lopez L.M., Kaptein A.A., Helmerhorst F.M. Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane Database Syst Rev 2009; 2: CD006586.
  • 12 Dante G., Facchinetti F. Herbal treatments for alleviating premenstrual symptoms: a systematic review. J Psychosom Obstet Gynaecol 2011; 32: 42-51.
  • 13 Whelan A.M., Jurgens T.M., Naylor H. Herbs, vitamins and minerals in the treatment of premenstrual syndrome: a systematic review. Can J Clin Pharmacol 2009; 16: e407-e429.
  • 14 Rocha Filho E.A., Lima J.C., Pinho Neto J.S., Montarroyos U. Essential fatty acids for premenstrual syndrome and their effect on prolactin and total cholesterol levels: a randomized, double blind, placebo-controlled study. Reprod Health 2011; 8: 2.
  • 15 Canning S., Waterman M., Orsi N., Ayres J., Simpson N., Dye L. The efficacy of Hypericum perforatum (St John's Wort) for the treatment of premenstrual syndrome: a randomized, double-blind, placebo-controlled trial. CNS Drugs 2010; 24: 207-225.
  • 16 Collins A., Cerin A., Coleman G., Landgren B.M. Essential fatty acids in the treatment of premenstrual syndrome. Obstet Gynecol 1993; 81: 93-98.
  • 17 Lepaisant C. [Clinical trials in homeopathy: treatment of mastodynia due to premenstrual syndrome]. [Article in French] Rev Fr Gynecol Obstet 1995; 90: 94-97.
  • 18 Yakir M., Kreitler S., Brzezinski A., Vithoulkas G., Oberbaum M., Bentwich Z. Effects of homeopathic treatment in women with premenstrual syndrome: a pilot study. Br Homeopath J 2001; 90: 148-153.
  • 19 True B.L., Goodner S.M., Burns E.A. Review of the etiology and treatment of premenstrual syndrome. Drug Intell Clin Pharm 1985; 19: 714-722.
  • 20 Smith M.A., Youngkin E.Q. Managing the premenstrual syndrome. Clin Pharm 1986; 5: 788-797.
  • 21 Freeman E.W., Rickels K. Characteristics of placebo responses in medical treatment of premenstrual syndrome. Am J Psychiatry 1999; 156: 1403-1408.